A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis

Erik Tenland, Nitya Krishnan, Anna Rönnholm, Sadaf Kalsum, Manoj Puthia, Matthias Mörgelin, Mina Davoudi, Magdalena Otrocka, Nader Alaridah, Izabela Glegola-Madejska, Erik Sturegård, Artur Schmidtchen, Maria Lerm, Brian D. Robertson, Gabriela Godaly

Research output: Contribution to journalArticlepeer-review

Abstract

Tuberculosis has been reaffirmed as the infectious disease causing most deaths in the world. Co-infection with HIV and the increase in multi-drug resistant Mycobacterium tuberculosis strains complicate treatment and increases mortality rates, making the development of new drugs an urgent priority. In this study we have identified a promising candidate by screening antimicrobial peptides for their capacity to inhibit mycobacterial growth. This non-toxic peptide, NZX, is capable of inhibiting both clinical strains of M. tuberculosis and an MDR strain at therapeutic concentrations. The therapeutic potential of NZX is further supported in vivo where NZX significantly lowered the bacterial load with only five days of treatment, comparable to rifampicin treatment over the same period. NZX possesses intracellular inhibitory capacity and co-localizes with intracellular bacteria in infected murine lungs. In conclusion, the data presented strongly supports the therapeutic potential of NZX in future anti-TB treatment.

Original languageEnglish
Pages (from-to)231-238
Number of pages8
JournalTuberculosis
Volume113
DOIs
Publication statusPublished - 2018

Subject classification (UKÄ)

  • Microbiology in the medical area

Free keywords

  • Antimicrobial peptides
  • Mycobacterium tuberculosis
  • Tuberculosis treatment

Fingerprint

Dive into the research topics of 'A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this